104 research outputs found

    Far Ultraviolet Spectra of B Stars near the Ecliptic

    Get PDF
    Spectra of B stars in the wavelength range of 911-1100 A have been obtained with the EURD spectrograph onboard the Spanish satellite MINISAT-01 with ~5 A spectral resolution. IUE spectra of the same stars have been used to normalize Kurucz models to the distance, reddening and spectral type of the corresponding star. The comparison of 8 main-sequence stars studied in detail (alpha Vir, epsilon Tau, lambda Tau, tau Tau, alpha Leo, zeta Lib, theta Oph, and sigma Sgr) shows agreement with Kurucz models, but observed fluxes are 10-40% higher than the models in most cases. The difference in flux between observations and models is higher in the wavelength range between Lyman alpha and Lyman beta. We suggest that Kurucz models underestimate the FUV flux of main-sequence B stars between these two Lyman lines. Computation of flux distributions of line-blanketed model atmospheres including non-LTE effects suggests that this flux underestimate could be due to departures from LTE, although other causes cannot be ruled out. We found the common assumption of solar metallicity for young disk stars should be made with care, since small deviations can have a significant impact on FUV model fluxes. Two peculiar stars (rho Leo and epsilon Aqr), and two emission line stars (epsilon Cap and pi Aqr) were also studied. Of these, only epsilon Aqr has a flux in agreement with the models. The rest have strong variability in the IUE range and/or uncertain reddening, which makes the comparison with models difficult.Comment: 25 pages, 6 figures, to be published in The Astrophysical Journa

    Effect of the topical administration of corticosteroids and tuberculin pre-sensitisation on the diagnosis of tuberculosis in goats

    Get PDF
    Background: Caprine tuberculosis (TB) is a zoonosis caused by members of the Mycobacterium tuberculosis complex (MTBC). Caprine TB control and eradication programmes have traditionally been based on intradermal tuberculin tests and slaughterhouse surveillance. However, this strategy has limitations in terms of sensitivity and specificity. Different factors may affect the performance of the TB diagnostic tests used in goats and, subsequently, the detection of TB-infected animals. In the present study, the effect of two of the factors that may affect the performance of the techniques used to diagnose TB in goats, the topical administration of corticosteroids and a recent pre-sensitisation with tuberculin, was analysed. Methods: The animals (n = 151) were distributed into three groups: (1) a group topically treated with corticosteroids 48 h after intradermal tuberculin tests (n = 53); (2) a group pre-sensitised with bovine and avian purified protein derivatives (PPDs) 3 days before the intradermal tuberculin test used for TB diagnosis (n = 48); and (3) a control group (n = 50). All the animals were tested using single and comparative intradermal tuberculin (SIT and CIT, respectively) tests, an interferon-gamma release assay (IGRA) and a P22 ELISA. Results: The number of SIT test reactors was significantly lower in the group treated with corticosteroids when compared to the pre-sensitised (p 0.05). No significant effect was observed on IGRA and P22 ELISA due to corticosteroids administration. Nevertheless, a previous PPD injection affected the IGRA performance in some groups. Conclusions: The application of topical corticosteroid 24 h before reading the SIT and CIT tests can reduce the increase in skin fold thickness and subsequently significantly decrease the number of positive reactors. Corticosteroids used can be detected in hair samples. A previous pre-sensitisation with bovine and avian PPDs does not lead to a significant reduction in the number of intradermal tests reactors. These results are valuable in order to improve diagnosis of caprine TB and detect fraudulent activities in the context of eradication programs.This study was funded by the “Analysis of the long-term caprine tuberculosis eradication process and development of diagnostic tests and control measures for its improvement (GoaTBfree-UCM)” Project (PID2019-105155RB-C31, Ministry of Science and Innovation of Spain) and the Ministry of Agriculture, Fisheries and Food of Spain. JO was supported by an FPU contract-fellowship (Formación de Profesorado Universitario) from the Spanish Ministerio de Ciencia, Innovación y Universidades (FPU18/05197).S

    Effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage (ACROBAT) in the UK: a protocol for a pilot cluster randomisedtrial

    Get PDF
    Introduction The incidence of severe postpartum haemorrhage (PPH) that requires blood transfusion is on the increase. Fibrinogen levels have been shown to drop early and significantly during PPH, which is associated with worse outcomes. Early fibrinogen replacement could potentially improve outcomes. No studies have investigated the clinical impact of early cryoprecipitate transfusion in PPH. Prior to performing a full-scale trial, a pilot study is needed to determine feasibility of the intervention and recruitment. Methods ACROBAT is a cluster-randomised pilot study with a qualitative evaluation. Four large London maternity units are randomised to either the intervention or control group. The intervention group will adapt their major obstetric haemorrhage procedures to administer cryoprecipitate early for primary PPH. The control group will retain their standard of care. We include women at >24 weeks gestation who are actively bleeding within 24 hours of delivery and for whom transfusion of red blood cells (RBCs) has been started. We exclude women who decline blood transfusions in advance or have inherited Factor XIII or fibrinogen deficiency. Due to the emergency nature of the intervention, informed consent for administering the intervention is waived. The primary objective is to assess the feasibility of administering cryoprecipitate within 90 min of RBC request, as compared with standard treatment where cryoprecipitate is given later or not at all. Secondary objectives include the feasibility of recruitment and data collection, reasons for and barriers to consent, preliminary maternal clinical outcomes, identification of the optimal infrastructure pathways for study delivery, and acceptability of the intervention and outcomes

    Genome comparison of erythromycin resistant campylobacter from Turkeys identifies hosts and pathways for horizontal spread of erm(B) genes

    Get PDF
    Los patógenos en el género Campylobacter son la causa más común de gastroenteritis bacteriana transmitida por los alimentos. La campilobacteriosis, causada principalmente por Campylobacter jejuni y Campylobacter coli, se transmite a los humanos mediante alimentos de origen animal, especialmente aves de corral. En cuanto a muchos patógenos, la resistencia antimicrobiana en Campylobacter está aumentando a un ritmo alarmante. La prescripción de eritromicina es el tratamiento de elección para los casos clínicos que requieren terapia antimicrobiana, pero esto se ve comprometido por la movilidad del gen de resistencia a la eritromicina erm (B) entre las cepas. Aquí, evaluamos la resistencia a seis antimicrobianos en 170 aislados de Campylobacter (133 C. coli y 37 C. jejuni) de pavos. Los aislados resistentes a la eritromicina (n = 85; 81 C. coli y 4 C. jejuni) se examinaron en busca de la presencia del gen erm (B), que no se ha identificado previamente en aislamientos de pavos. Se secuenciaron los genomas de dos aislamientos positivos de C. coli y en ambos aislamientos el gen erm (B) se agrupó con determinantes de resistencia contra aminoglucósidos más tetraciclina, incluidos aad9, aadE, aph (2 ") - IIIa, aph (3 ') - IIIa , y genes tet (O). El análisis genómico comparativo identificó secuencias erm (B) idénticas entre Campylobacter de pavos, Streptococcus suis de cerdos y Enterococcus faecium y Clostridium difficile de humanos. Esto es consistente con múltiples eventos de transferencia horizontal entre diferentes especies de bacterias que colonizan pavos. Este ejemplo destaca el potencial de diseminación de la resistencia antimicrobiana a través de los límites de las especies bacterianas que pueden comprometer su efectividad en la terapia antimicrobiana.Pathogens in the genus Campylobacter are the most common cause of food-borne bacterial gastro-enteritis. Campylobacteriosis, caused principally by Campylobacter jejuni and Campylobacter coli, is transmitted to humans by food of animal origin, especially poultry. As for many pathogens, antimicrobial resistance in Campylobacter is increasing at an alarming rate. Erythromycin prescription is the treatment of choice for clinical cases requiring antimicrobial therapy but this is compromised by mobility of the erythromycin resistance gene erm(B) between strains. Here, we evaluate resistance to six antimicrobials in 170 Campylobacter isolates (133 C. coli and 37 C. jejuni) from turkeys. Erythromycin resistant isolates (n = 85; 81 C. coli and 4 C. jejuni) were screened for the presence of the erm(B) gene, that has not previously been identified in isolates from turkeys. The genomes of two positive C. coli isolates were sequenced and in both isolates the erm(B) gene clustered with resistance determinants against aminoglycosides plus tetracycline, including aad9, aadE, aph(2″)-IIIa, aph(3′)-IIIa, and tet(O) genes. Comparative genomic analysis identified identical erm(B) sequences among Campylobacter from turkeys, Streptococcus suis from pigs and Enterococcus faecium and Clostridium difficile from humans. This is consistent with multiple horizontal transfer events among different bacterial species colonizing turkeys. This example highlights the potential for dissemination of antimicrobial resistance across bacterial species boundaries which may compromise their effectiveness in antimicrobial therapy.• Ministerio de Ciencia e Innovación. Ayudas AGL2009-07550, AGL2012-39028 • Ministerio de Agricultura, Alimentación y Medio Ambiente. Ayuda 2014/000223 • Comunidad Autónoma de Madrid. Ayudas S2009 / AGR-1489; S2013 / ABI-2747 • Ministerio de Economía y Competitividad de España. Ayuda AGL2012-39028 • Ministerio de Economía y Competitividad. Beca BES-2013-065003, para Diego Flórez Cuadrado • Consejo de Investigación Médica. Ayuda MR / L015080 / 1, para Samuel K. SheppardpeerReviewe

    Eradication of bovine tuberculosis at a herd-level in Madrid, Spain: study of within-herd transmission dynamics over a 12 year period

    Get PDF
    BACKGROUND Eradication of bovine tuberculosis (bTB) through the application of test-and-cull programs is a declared goal of developed countries in which the disease is still endemic. Here, longitudinal data from more than 1,700 cattle herds tested during a 12 year-period in the eradication program in the region of Madrid, Spain, were analyzed to quantify the within-herd transmission coefficient (β) depending on the herd-type (beef/dairy/bullfighting). In addition, the probability to recover the officially bTB free (OTF) status in infected herds depending on the type of herd and the diagnostic strategy implemented was assessed using Cox proportional hazard models. RESULTS Overall, dairy herds showed higher β (median 4.7) than beef or bullfighting herds (2.3 and 2.2 respectively). Introduction of interferon-gamma (IFN-γ) as an ancillary test produced an apparent increase in the β coefficient regardless of production type, likely due to an increase in diagnostic sensitivity. Time to recover OTF status was also significantly lower in dairy herds, and length of bTB episodes was significantly reduced when the IFN-γ was implemented to manage the outbreak. CONCLUSIONS Our results suggest that bTB spreads more rapidly in dairy herds compared to other herd types, a likely cause being management and demographic-related factors. However, outbreaks in dairy herds can be controlled more rapidly than in typically extensive herd types. Finally, IFN-γ proved its usefulness to rapidly eradicate bTB at a herd-level

    Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Get PDF
    Multiple myeloma (MM) remains as an incurable disease and, although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach, most patients ultimately relapse, and their treatment remains challenging. Because allo-HSCT can modify not only the biology of the disease, but also the immune system and the microenvironment, it can potentially enhance the response to rescue therapies. Information on the efficacy and safety of novel drugs in patients relapsing after allo-HSCT is lacking, however. The objectives of this study were to evaluate the efficacy and toxicity of rescue therapies in patients with MM who relapsed after allo-HSCT, as well as to compare their efficacy before and after allo-HSCT. This retrospective multicenter study included 126 consecutive patients with MM who underwent allo-HSCT between 2000 and 2013 at 8 Spanish centers. All patients engrafted. The incidence of grade II-IV acute graft-versus-host disease (GVHD) was 47%, and nonrelapse mortality within the first 100 days post-transplantation was 13%. After a median follow-up of 92 months, overall survival (OS) was 51% at 2 years and 43% at 5 years. The median progression-free survival after allo-HSCT was 7 months, whereas the median OS after relapse was 33 months. Patients relapsing in the first 6 months after transplantation had a dismal prognosis compared with those who relapsed later (median OS, 11 months versus 120 months; P <.001). The absence of chronic GVHD was associated with reduced OS after relapse (hazard ratio, 3.44; P <.001). Most patients responded to rescue therapies, including proteasome inhibitors (PIs; 62%) and immunomodulatory drugs (IMiDs; 77%), with a good toxicity profile. An in-depth evaluation, including the type and intensity of PI- and IMiD-based combinations used before and after allo-HSCT, showed that the overall response rate and duration of response after allo-HSCT were similar to those seen in the pretransplantation period. Patients with MM who relapse after allo-HSCT should be considered candidates for therapy with new drugs, which can achieve similar response rates with similar durability as seen in the pretransplantation period. This pattern does not follow the usual course of the disease outside the transplantation setting, where response rates and time to progression decreases with each consecutive line of treatment

    Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model

    Get PDF
    This economic evaluation showed a screening intervention with a major health gain that also produced net savings when a long follow-up was used to capture the late economic benefit. The number of colonoscopies required was high but remain within the capacity of the Basque Health Service. So far in Europe, no other population Colorectal Cancer screening programme has been evaluated by budget impact analysis

    Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study

    Get PDF
    Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p&lt;0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p&lt;0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised
    corecore